• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 2 filed

    12/21/20 9:38:55 AM ET
    $RELV
    Major Pharmaceuticals
    Health Care
    Get the next $RELV alert in real time by email
    25 1 relv20201218_25.htm FORM 25 relv20201218_25.htm

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D. C. 20549

     

    FORM 25

     

    NOTIFICATION OF REMOVAL FROM LISTING AND/OR

    REGISTRATION UNDER SECTION 12(b) OF THE

    SECURITIES EXCHANGE ACT OF 1934.

     

    Commission File Number 001-19932

     

    RELIV INTERNATIONAL, INC.

     

    THE NASDAQ STOCK MARKET LLC

    (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

     

    136 Chesterfield Industrial Blvd.

    Chesterfield, Missouri 63005

    (636) 537-9715

    (Address, including zip code, and telephone number, including area code, of Issuer’s principal executive offices)

     

    Common Stock, par value $0.001 per share

    (Description of class of securities)

     

    Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

     

     

    ☐

    17CFR240.12d2-2(a)(1)

     

     

    ☐

    17 CFR 240.12d2-2(a)(2)

     

     

    ☐

    17 CFR 240.12d2-2(a)(3)

     

     

    ☐

    17 CFR 240.12d2-2(a)(4)

     

     

    ☐

    Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange.

     

     

    ☒

    Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with the rules of the Exchange and the requirements of 17 CFR 240.12d2-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

     

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, Reliv International, Inc. certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

     

    Date: December 21, 2020

     

    By: /s/ Steven D. Albright

     

    Title: Senior Vice President and Chief Financial Officer

     

     

    Name: Steven D. Albright

     

     

     

     
    Get the next $RELV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RELV

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $RELV
    SEC Filings

    View All

    SEC Form 15-12G filed

    15-12G - RELIV INTERNATIONAL INC (0000768710) (Filer)

    1/19/21 9:42:44 AM ET
    $RELV
    Major Pharmaceuticals
    Health Care

    SEC Form SC 13E3/A filed

    SC 13E3/A - RELIV INTERNATIONAL INC (0000768710) (Subject)

    1/19/21 9:32:57 AM ET
    $RELV
    Major Pharmaceuticals
    Health Care

    SEC Form 8 filed

    8-K - RELIV INTERNATIONAL INC (0000768710) (Filer)

    12/23/20 11:34:31 AM ET
    $RELV
    Major Pharmaceuticals
    Health Care

    $RELV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Reliv International, Inc. Announces Update to its Reverse Stock Split Transaction and Plan to Delist from NASDAQ and Deregister its Common Stock

    CHESTERFIELD, Mo., Dec. 4, 2020 /PRNewswire/ -- Reliv International, Inc. (NASDAQ:RELV), a developer and marketer of nutritional supplements that promote optimal health, today announced an update to its plan to suspend its obligations to file periodic and current reports and other information with the U.S. Securities and Exchange Commission (the "Commission") under the Securities Exchange Act of 1934, as amended (the "Exchange Act") and to delist its common stock from trading on the NASDAQ Stock Exchange as previously announced in a press release on October 19, 2020. December 21, 2020 will be the effective date of the Company's 1-for-2,000 reverse stock split (the "Reverse Split") of its

    12/4/20 4:15:00 PM ET
    $RELV
    Major Pharmaceuticals
    Health Care